Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells.

@article{Yee2004SynergisticEO,
  title={Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells.},
  author={Kevin W. H. Yee and Marcus Matthias Schittenhelm and Anne-Marie O'farrell and Ajia R Town and Laura S. McGreevey and Troy Bainbridge and Julie M. Cherrington and Michael C Heinrich},
  journal={Blood},
  year={2004},
  volume={104 13},
  pages={4202-9}
}
Fetal liver tyrosine kinase 3 internal tandem duplication (FLT3 ITD) mutations are the most common molecular abnormality associated with adult acute myeloid leukemia (AML). To exploit this molecular target, a number of potent and specific FLT3 kinase inhibitors have been developed and are currently being tested in early phase clinical trials of patients with refractory AML. To explore the efficacy of combining a FLT3 inhibitor with standard AML chemotherapy drugs, we tested the effect of… CONTINUE READING
44 Citations
54 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 44 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 54 references

Final results of a phase I and pharmacokinetic study of SU11248, a novel multi-target tyrosine kinase inhibitor, in patients with advanced cancers [abstract

  • E Raymond, S Faivre, K Vera
  • Proc Am Soc Clin Oncol
  • 2003

Phase I trial of SU011248, a novel tyrosine kinase inhibitor in advanced solid tumors [abstract

  • L Rosen, M Mulay, J Long
  • Proc Am Soc Clin Oncol
  • 2003

Similar Papers

Loading similar papers…